Highlights of weekly biotech stock moves

Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.20 (12%) to $30.87 on Monday after reporting preliminary 4Q10 and 2010 sales figures for Ampyra dalfampridine of $55.7 million and $141.4 million, respectively. Acorda launched the product last March to improve walking ability in patients with multiple sclerosis (MS).

On Tuesday, Biogen Idec Inc. (NASDAQ:BIIB), which has ex-U.S. rights, said Health Canada issued a letter of deficiency for an NDS for the product. Details weren't disclosed...